<DOC>
	<DOC>NCT02568878</DOC>
	<brief_summary>- Assess the antidepressant/anxiolytic effect of creatine in male and female methamphetamine users - Assess creatine's effect on methamphetamine use - Assess the safety of creatine in male methamphetamine users with depression</brief_summary>
	<brief_title>Creatine for Depressed Male and Female Methamphetamine Users</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Methamphetamine</mesh_term>
	<criteria>Current primary diagnosis of methamphetamine dependence or abuse, with methamphetamine preferred drug of abuse Current diagnosis of major depressive disorder (primary or substanceinduced) Current diagnosis of an anxiety disorder (primary or substanceinduced) Current Hamilton Depression Rating scale score &gt; or = to 16 Current Hamilton Anxiety Scale score &gt; = to 18 If taking a psychotropic medication for depressed or anxious mood, regimen must be stable for &gt; = to 4 weeks prior to creatine treatment initiation Persons unable to provide adequate informed consent Persons who are at clinically significant suicidal or homicidal risk Primary substancerelated diagnosis other than methamphetamine dependence or abuse Positive pregnancy test (females only) History of renal disease Clinically significant medical or neurological illness identified by history, physical exam and laboratory testing History of hypersensitivity reaction to creatine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Depression</keyword>
	<keyword>Anxiety</keyword>
	<keyword>Methamphetamine dependence</keyword>
</DOC>